Fig. 4: Functional BCL-2 dependence indicates in vivo preclinical antileukemia activity in an independent cohort of patient-derived ALL samples.
From: Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
Individual patient-derived ALL xenograft samples (BCP-ALL N = 5, T-ALL N = 3) were transplanted onto groups of recipient mice and treated with either VEN or vehicle. After treatment, mice were regularly monitored for the appearance of leukemia cells (≥5% or more of mCD45−huCD45+huCD19+ or huCD7+) in the peripheral blood. a Survival times of leukemia bearing mice treated with VEN (gray bars) or vehicle (black bars, left diagram) and corresponding VEN-induced survival differences (‘delta survival’, right diagram). b Significant association of functional BCL-2 dependence (mitochondrial BAD-HRK priming) with preclinical VEN sensitivities of ALL in vivo (linear regression; R2, correlation coefficient; p, significance) and c high predictive value for post-VEN survival (ROC/receiver operating characteristic curve; AUC, area under the curve; p, significance)
